Closure of Trading Window
Earkart Ltd operates in Medical Equipment & Supplies within the Healthcare sector.
160 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Corporate actions, results dates and filings will appear here once ingested.
Standalone figures
| Ratio | Mar 2026 |
|---|---|
| Margins | |
| Gross margin % | 39.1% |
| EBITDA margin % | 15.5% |
| EBIT margin % | 14.2% |
| PAT margin % | 9.1% |
| Working capital | |
| Receivable days | 142 |
| Inventory days | 121 |
| Payable days | 20 |
| NWC days | 243 |
| Leverage | |
| Current ratio | 12.67 |
| Debt to EBITDA | 0 |
| Debt to equity | 0 |
| Interest coverage | 14.4 |
| Asset turnover | 0.78 |
| Return ratios | |
| Return on assets % | 7.1% |
| Return on capital employed % | 12.1% |
| Return on equity % | 7.7% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Promoter holding up 0 percentage points since Sep 2025.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Documents link to external sources (exchange filings, company investor pages).
No scheme among the 32 fund houses on record reported a position in Earkart Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics LimitedMOLBIOMOLBIO | ₹17,431 Cr | ₹17,844 Cr | ₹1,020 Cr | ₹262 Cr | 25.7% | ₹145 Cr | 13.6% | 23.7% | 16.2% | — |
| Poly Medicure LimitedPOLYMEDPOLYMED | ₹16,610 Cr | ₹16,952 Cr | ₹1,997 Cr | ₹461 Cr | 23.6% | ₹315 Cr | 17.1% | 14.5% | 11% | 294 |
| Fischer Medical Ventures LimitedFISCHERFISCHER | ₹2,190 Cr | ₹2,262 Cr | ₹367 Cr | ₹50 Cr | 14% | ₹30 Cr | 10.1% | 13.6% | 8.6% | 111 |
| Tarsons Products LimitedTARSONSTARSONS | ₹1,752 Cr | ₹2,135 Cr | ₹441 Cr | ₹119 Cr | 27.9% | ₹11 Cr | 3.4% | 5% | 2.3% | 361 |
| Laxmi Dental LimitedLAXMIDENTLLAXMIDENTL | ₹1,066 Cr | ₹1,066 Cr | ₹287 Cr | ₹46 Cr | 15.6% | ₹31 Cr | 10.4% | 14.7% | 12.8% | 109 |
| Hemant Surgical Industries LtdHSILHSIL | ₹885 Cr | — | ₹232 Cr | ₹23 Cr | 10% | ₹18 Cr | 7.9% | — | — | — |
| Fabtech Technologies LimitedFABTECHFABTECH | ₹632 Cr | ₹675 Cr | ₹418 Cr | ₹45 Cr | 8.5% | ₹49 Cr | 9.3% | 15.5% | 12.9% | 55 |
| Prevest Denpro LtdPREVESTPREVEST | ₹452 Cr | — | ₹72 Cr | ₹25 Cr | 34.4% | ₹20 Cr | 28.5% | — | — | — |
| Nureca LimitedNURECANURECA | ₹332 Cr | ₹333 Cr | ₹153 Cr | ₹4 Cr | 0.1% | ₹4 Cr | 1.4% | 3.3% | 1.1% | 186 |
| Earkart LtdEARKARTEARKART | ₹179 Cr | ₹179 Cr | ₹54 Cr | ₹8 Cr | 15.5% | ₹5 Cr | 9.1% | 12.1% | 7.7% | 243 |
| Choksi Asia LtdCHOKSICHOKSI | ₹117 Cr | ₹119 Cr | ₹11 Cr | ₹-2 Cr | 13.8% | ₹2 Cr | 10.8% | 18.9% | 13.5% | 142 |
| Shree Pacetronix LtdSHREEPACSHREEPAC | ₹68 Cr | ₹71 Cr | ₹8 Cr | ₹1 Cr | 23.5% | ₹0 Cr | 14% | 27.4% | 18.9% | 385 |
| Date | Category | Subject | Filing |
|---|---|---|---|
| 28 Sept 2026, 4:45 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window |
| ₹ Cr | Mar 2026 |
|---|---|
| Revenue | 54 |
| COGS | 33 |
| Gross profit | 21 |
| 13 | |
| 8 | |
| OPM % | 15.5% |
| Depreciation | 1 |
| Interest | 1 |
| 0 | |
| Profit before tax | 7 |
| Tax | 2 |
| Tax % | 32% |
| PAT | 5 |
| PAT margin % | 9.1% |
| EPS (₹) | 8 |
| EPS adjusted (₹) | 3.6 |
| Annual report | Annual report for Mar 2026 |
| ₹ Cr | Mar 2026 |
|---|---|
| Equity capital | 14 |
| Reserves | 51 |
| 0 | |
| 5 | |
| Total equity & liabilities | 69 |
| 6 | |
| CWIP | 0 |
| Investments | 0 |
| 63 | |
| Total assets | 69 |
| ₹ Cr | Mar 2026 |
|---|---|
| -13 | |
| -5 | |
| 39 | |
| Net cash flow | 21 |
| Free cash flow | -18 |
| CFO / Operating profit % | -150.4% |